Product sheet

[illegible] B-LCL-HROC112 | 302023

[illegible]

Description	B-LCL-HROC112 [illegible] (EBV) [illegible] B [illegible] B [illegible], [illegible]. [illegible], B-LCL-HROC112 [illegible] B [illegible], [illegible] CD19 [illegible]-CD20, [illegible] [illegible], B-LCL-HROC112 [illegible] ([illegible], IgG, IgM [illegible] IgA), [illegible]
Organism	[illegible]
Tissue	[illegible]
Disease	[illegible]
Metastatic site	Not applicable (EBV-transformed B-LCL from CRC patient; suspension culture)
Applications	T cell and NK cell assays; HLA typing; antigen presentation studies; CTL assay target cells; colorectal cancer immunology; patient-matched HROC biobank studies
Synonyms	B-LCL CO112, Bc HROC112

[illegible]

Age	80 [illegible]
Gender	[illegible]
Ethnicity	Caucasian
Morphology	[illegible]
Cell type	[illegible] B
Growth properties	[illegible]

[illegible]

Citation	B-LCL-HROC112 ([illegible] Cytion 302023)

[redacted] B-LCL-HROC112 | 302023

Biosafety level	2
NCBI_TaxID	9606
CellosaurusAccession	Not assigned
GMO Status	GMO-S2: This B-LCL contains a stably maintained EBV episome (EBNA-1/-2/-3, LMP-1/-2). EBV is classified as risk group 2; BSL-2 containment required. This classification applies within Germany; regulations may differ elsewhere.

[redacted]

Viruses	[redacted]: EBV

[redacted]

Culture Medium	RPMI 1640, w: 2.0 mM [redacted], w: 2.0 g/L NaHCO3 ([redacted] Cytion 820700a)
Supplements	[redacted] 10% FBS
Subculturing	[redacted] 5×10^5 [redacted]
Freeze medium	[redacted], [redacted] (FBS) + 10% DMSO [redacted], [redacted]

[redacted] B-LCL-HROC112 | 302023

Thawing and Culturing Cells	1. [redacted] 2. [redacted] 3. [redacted] 4. [redacted] 70% [redacted] 5. [redacted] 15 [redacted] 8 [redacted] 6. [redacted] 7. [redacted] 8. [redacted]
Incubation Atmosphere	37°C, 5% CO_2, [redacted]
Flask Coating	[redacted]
Freezing Procedure	[redacted]
Shipping Conditions	[redacted]
Storage Conditions	[redacted]

[redacted] / [redacted] / HLA

Sterility	[redacted] PCR [redacted] [redacted]